Literature DB >> 6816132

Treatment of the "on-off" phenomenon in Parkinsonism with lithium carbonate.

C E Coffey, D R Ross, E L Ferren, J L Sullivan, C W Olanow.   

Abstract

Six patients with severe parkinsonism complicated by the "on-off" phenomenon were treated with lithium carbonate in addition to regular antiparkinson medications. A randomized double-blind crossover trial of lithium versus placebo was conducted, followed by an open trial of lithium therapy. Five patients had markedly reductions in akinesia (mean, 70%) and improved by one grade in Parkinson staging. This result was more striking in male than in female patients, and in all responders benefit has been maintained during the open phase of lithium treatment (mean follow-up of 36 weeks). In no patient was a reduction in akinesia observed during placebo treatment. Lithium carbonate appears to offer a new and potentially effective approach to treatment of the on-off phenomenon.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6816132     DOI: 10.1002/ana.410120410

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  4 in total

Review 1.  Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Pharmacol Ther       Date:  2010-08-10       Impact factor: 12.310

2.  The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy.

Authors:  Carol A Lazzara; Rebeccah R Riley; Anand Rane; Julie K Andersen; Yong-Hwan Kim
Journal:  Brain Res       Date:  2015-06-26       Impact factor: 3.252

3.  Lithium does not interact with haloperidol in the dopaminergic pathways of the rat brain.

Authors:  A Reches; V Jackson-Lewis; S Fahn
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 4.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.